# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
CEOs of Palantir, Oracle, and Pfizer lobbied US senators for support of Israel during Gaza invasion and discussed solutions for...
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its bloc...
The FDA has approved Merck's Capvaxive, the first pneumococcal conjugate vaccine for adults, protecting against 21 strains ...
Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.
Kansas has filed a lawsuit against Pfizer, Inc., alleging the company misled the public about the safety and effectiveness of i...
https://www.foxbusiness.com/politics/kansas-sues-pfizer-over-misrepresentations-adverse-affects-covid-19-vaccine
- Reuters
Patients in MagnetisMM-3 demonstrated a median overall survival (OS) of 24.6 months, with median progression-free survival (P...